TWi Biotechnology, Inc.
6610
Rank in Stocks
#18966
TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm,... TWi Biotechnology, Inc. operates as a clinical-stage biopharmaceutical firm, concentrating on the development and sale of medications designed to address innate immunity disorders, primarily within Taiwan. The company's drug pipeline notably includes AC-203, which is currently undergoing Phase 2 clinical trials for various conditions such as epidermolysis bullosa simplex, epidermolysis bullosa, arthritis, gout, and diabetes mellitus. Additionally, AC-1101 is in Phase 1 trials for vitiligo treatment and is advancing through preclinical stages for atopic dermatitis, granuloma annulare, and other uncommon autoimmune skin diseases. TWi Biotechnology has also established a drug development collaboration with Hong Kong Winhealth Pharma Group Co., Limited, targeting the markets of Mainland China, Hong Kong, and Macao. Founded in 2010, the company is headquartered in Taipei, Taiwan.
Share Price
$0.52890536
Last synced: 2026-11-10
Market Cap
$117.90M
Change (1 day)
-2.53%
Change (1 year)
-54.28%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade TWi Biotechnology, Inc. (6610)
Category
Healthcare
Operating Margin for TWi Biotechnology, Inc. (6610)
Operating Margin as of November 2026 TTM: 0.00%
According to TWi Biotechnology, Inc.'s latest financial reports, its current operating margin (TTM) is 0.00%. At the end of 2025 the company had an operating margin of 0.00%.
Operating Margin history for TWi Biotechnology, Inc. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 0.00% | 0.00% |
| 2025 | 0.00% | 0.00% |
| 2024 | 0.00% | 0.00% |
| 2023 | 0.00% | 0.00% |
| 2022 | 0.00% | -100.00% |
| 2021 | -23.04% | -99.71% |
| 2020 | -7,909.95% | 570.90% |
| 2019 | -1,179.01% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | - |
US
|
|
| -149.01% | - |
US
|
|
| 25.57% | - |
AU
|
|
| 31.23% | - |
BE
|
|
| 29.35% | - |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about TWi Biotechnology, Inc.'s operating margin
What was TWi Biotechnology, Inc.'s operating margin in 2025?
In 2025, TWi Biotechnology, Inc.'s operating margin was 0.00%, compared with 0.00% in 2024.
How has TWi Biotechnology, Inc.'s operating margin changed since 2020?
From 2020 to 2025, TWi Biotechnology, Inc.'s operating margin was highest in 2025 (0.00%) and lowest in 2020 (-7,909.95%).
How does TWi Biotechnology, Inc.'s operating margin compare with similar companies?
TWi Biotechnology, Inc.'s operating margin (0.00%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.